Comparative Study
doi: 10.1016/s0924-8579(00)00337-x.
In vitro activity of four fluoroquinolones against Mycobacterium tuberculosis
Affiliations
- PMID: 11282270
- DOI: 10.1016/s0924-8579(00)00337-x
Item in Clipboard
Comparative Study
In vitro activity of four fluoroquinolones against Mycobacterium tuberculosis
Int J Antimicrob Agents.
2001 Mar.
Abstract
The in vitro activity of ciprofloxacin, ofloxacin, levofloxacin and moxifloxacin against strains of Mycobacterium tuberculosis was studied. Moxifloxacin and levofloxacin showed the greatest activity having an MIC(90) of 1 mg/l. The MIC(90) for ofloxacin was 2 mg/l and for ciprofloxacin 4 mg/l. Further studies should be made to determine the role played by these compounds in the treatment of tuberculosis.
Similar articles
-
In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis.Int J Antimicrob Agents. 2002 Dec;20(6):464-7. doi: 10.1016/s0924-8579(02)00239-x. Int J Antimicrob Agents. 2002. PMID: 12458143
-
Comparison of the bactericidal activity of various fluoroquinolones against Mycobacterium tuberculosis in an in vitro experimental model.J Antimicrob Chemother. 2011 Oct;66(10):2281-3. doi: 10.1093/jac/dkr281. Epub 2011 Jul 6. J Antimicrob Chemother. 2011. PMID: 21733966
-
In vitro activity of fluoroquinolones against Mycobacterium tuberculosis.J Chemother. 2005 Apr;17(2):169-73. doi: 10.1179/joc.2005.17.2.169. J Chemother. 2005. PMID: 15920901
-
Rapid assays for fluoroquinolone resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis.J Antimicrob Chemother. 2010 Aug;65(8):1551-61. doi: 10.1093/jac/dkq202. Epub 2010 Jun 11. J Antimicrob Chemother. 2010. PMID: 20542907 Review.
-
Prospects for development of new antimycobacterial drugs.J Infect Chemother. 2000 Mar;6(1):8-20. doi: 10.1007/s101560050043. J Infect Chemother. 2000. PMID: 11810525 Review.
Cited by
-
The resistance mechanisms of bacteria against ciprofloxacin and new approaches for enhancing the efficacy of this antibiotic.Front Public Health. 2022 Dec 21;10:1025633. doi: 10.3389/fpubh.2022.1025633. eCollection 2022. Front Public Health. 2022. PMID: 36620240 Free PMC article. Review.
-
Moxifloxacin-Mediated Killing of Mycobacterium tuberculosis Involves Respiratory Downshift, Reductive Stress, and Accumulation of Reactive Oxygen Species.Antimicrob Agents Chemother. 2022 Sep 20;66(9):e0059222. doi: 10.1128/aac.00592-22. Epub 2022 Aug 17. Antimicrob Agents Chemother. 2022. PMID: 35975988 Free PMC article.
-
Recent Progress and Challenges for Drug-Resistant Tuberculosis Treatment.Pharmaceutics. 2021 Apr 21;13(5):592. doi: 10.3390/pharmaceutics13050592. Pharmaceutics. 2021. PMID: 33919204 Free PMC article. Review.
-
Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.Trials. 2019 Jan 16;20(1):57. doi: 10.1186/s13063-018-3053-1. Trials. 2019. PMID: 30651149 Free PMC article.
-
A Review of Moxifloxacin for the Treatment of Drug-Susceptible Tuberculosis.J Clin Pharmacol. 2017 Nov;57(11):1369-1386. doi: 10.1002/jcph.968. Epub 2017 Jul 24. J Clin Pharmacol. 2017. PMID: 28741299 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
